Clinical trial
Calcium With or Without Estrogen and/or Risedronate in Preventing Osteoporosis…
NCT00043069 · Alliance for Clinical Trials in Oncology, Other · Completed
Key facts
| NCT number | NCT00043069 |
|---|---|
| Title | Calcium With or Without Estrogen and/or Risedronate in Preventing Osteoporosis in Patients With Prostate Cancer |
| Official title | Osteoporosis Prevention in Prostate Cancer Patients Receiving Androgen Ablation Therapy: A Phase III Randomized, Placebo-Controlled, Double-Blind Study |
| Lead sponsor | Alliance for Clinical Trials in Oncology, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Osteoporosis, Prostate Cancer |
| Intervention type | Dietary Supplement, Drug, Other |
| Interventions | calcium carbonate, cholecalciferol, Estrogen Antagonists, risedronate sodium, placebo |
| Enrollment | 71 |
| Start date | Nov 1, 2002 |
| Primary completion | Jun 1, 2006 |
| Completion | Jan 1, 2010 |
| First posted | Jan 27, 2003 |
| Last update posted | Dec 7, 2016 |
| Countries | Canada, United States |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: